Allergy Asthma Immunol Res.  2018 Jan;10(1):88-94. 10.4168/aair.2018.10.1.88.

Real-Life Clinical Use of Symbicort® Maintenance and Reliever Therapy for Asthmatic Patients in Korea

Affiliations
  • 1Department of Internal Medicine, Eulji University School of Medicine, Daejeon, Korea.
  • 2Department of Internal Medicine, Eulji University Hospital, Seoul, Korea.
  • 3Department of Allergy and Clinical Immunology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
  • 4Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea. hjyoon@hanyang.ac.kr
  • 5Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • 6Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.
  • 7Department of Internal Medicine, Inje University College of Medicine, Ilsan, Korea.
  • 8Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.
  • 9Medical Department, AstraZeneca Korea, Seoul, Korea.

Abstract

The aim of this study was to examine the daily practice patterns of Symbicort® Maintenance and Reliever Therapy (SMART) in Korean asthmatic patients and to analyze clinical signs related to overuse. This study used an observational, multicenter, noninterventional, prospective, uncontrolled design for examining asthmatic patients prescribed SMART to assess the frequency and pattern of Symbicort® usage as a maintenance and reliever medication. The characteristics of patients showing signs of overuse (frequency of inhalation: 8 or more times per day) were also analyzed. Among the 1,518 patients analyzed, 1,292 (85.1%) completed the trial. The number of mean inhalations per day was 2.14±1.15; the number of patients who had at least 1 as needed usage (PRN) inhalation per day was 843 (55.5%); the mean frequency of PRN use was 0.25±0.67 inhalations per day. The number of patients who overused for at least 1 day was 260 (17.1%). In particular, young patients, patients with limited physical activity, and patients with nocturnal symptoms demonstrated high frequency of overuse. The frequency of overuse during SMART was not high in Korean asthmatic patients and the asthma status of follow-up outpatients improved overall. However, there is a need for careful education targeted toward younger patients, patients with limited physical activity, and patients with nocturnal symptoms owing to their tendency to frequently overuse.

Keyword

Symbicort® maintenance and reliever therapy; budesonide; formoterol; prescription drug overuse; asthma

MeSH Terms

Asthma
Budesonide
Education
Follow-Up Studies
Formoterol Fumarate
Humans
Inhalation
Korea*
Motor Activity
Outpatients
Prescription Drug Overuse
Prospective Studies
Budesonide
Formoterol Fumarate
Full Text Links
  • AAIR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error